TechCrunch
Agentic.Plumbing raises $50M to embed AI in toilets for cancer detection
FDA 510(k) submitted· decision Q3–Q4 2026
Building the infrastructure to save 488 million lives.
Agentic.Plumbing (APT) is developing the world's first FDA-cleared autonomous diagnostic platform embedded in plumbing infrastructure. We're establishing global clinical partnerships ahead of approval.
Backed bya16zSequoiaMayo Clinic Ventures
Confidential · Clinical partners only
Prototype shown. Final design pending FDA approval.
Complete
$50M Series A
a16z · Sequoia · Mayo Ventures
In progress
FDA 510(k) submitted
Approval Q3–Q4 2026
In progress
Mayo Clinic partnership
In active negotiation
In progress
JAMA publication
Trial results Q4 2026
Where we are today
Transparent progress toward approval.
Q2 2024
Concept validation
MIT/Stanford team, Mayo oncologist collaboration, $8M seed.
Complete
Q1 2025
Prototype developed
Working device, 50-patient pilot, biomarker validation.
Complete
Q2 2026
FDA 510(k) submitted
Series A ($50M), Flex manufacturing partnership.
Complete
Q3–Q4 2026
Approval expected
Multi-center trials (500 patients), JAMA submission.
In progress
Q1–Q2 2027
Commercial launch
FDA clearance, CE Mark, waitlist fulfillment begins.
Planned
Clinical partnerships
Partner with us to validate the future of diagnostics.
We're selecting 10–15 launch partners globally — academic medical centers, integrated health systems, and global hospital networks.
Validation Partner
Academic medical centers, cancer institutes
Commitment100-patient trial, co-publication
Timeline6–12 months
- ✓Early data access
- ✓JAMA authorship
- ✓Thought leadership
Pilot Partner
Most activeIntegrated health systems, ACOs
Commitment1,000-patient deployment, outcomes study
Timeline12–24 months
- ✓Early access
- ✓Preferential pricing
- ✓Custom integrations
Co-Development
Global hospital networks, MedTech
CommitmentStrategic alliance, IP licensing
Timeline24+ months
- ✓Market exclusivity
- ✓Revenue share
- ✓Co-branding
Active partner pipeline
Mayo Clinic
Active negotiation
In progress
Johns Hopkins
Pilot discussions
In progress
Cleveland Clinic
Exploratory phase
In progress
Your institution
Open
Open
Early clinical evidence
Preliminary signal across four cancers.
Preliminary data. Pilot study (n=50). Multi-center validation trials underway. Not yet peer-reviewed. FDA clearance pending.
| Cancer | Detection window (pre-symptom) | Sensitivity (CI) | Specificity (CI) | Status |
|---|---|---|---|---|
| Pancreatic | 18 months | 89% (78–96%) | 94% (89–97%) | Validation trial |
| Colorectal | 14 months | 91% (84–96%) | 92% (87–95%) | Validation trial |
| Bladder | 12 months | 86% (76–93%) | 88% (82–93%) | Validation trial |
| Kidney | 16 months | 84% (73–92%) | 90% (84–94%) | Validation trial |
Full methodology and validation design in the Technical White Paper.
Download white paper →How it works
Agentic AI meets humanity's most universal infrastructure.
Agentic AI
- Autonomous multi-step reasoning without human input
- 50+ biomarker correlation analysis
- Personalized baseline per individual physiology
- 100% local edge processing — HIPAA-aligned
Technical questions?Schedule engineering call →
Institutional backing
Backed by leading healthcare & technology investors.
$50M
Series A raised
$400B
Total addressable market
488M
Lives saved (20-yr model)
12
Patents pending
Andreessen HorowitzSequoia CapitalMayo Clinic VenturesNIH SBIREuropean Innovation Council
Featured in
Third-party validation.
WIRED
The bathroom will be your doctor's office — here's how
MIT Technology Review
10 Breakthrough Technologies 2026: Agentic Diagnostics
The Economist
Plumbing meets AI: the unglamorous tech that could save millions
JAMA
Novel approach to pancreatic cancer screening shows promise (pending)
Nature Medicine
Continuous biomarker monitoring: a paradigm shift? (commentary)
TIME
Best Inventions of 2026 — APT nominated
Fast Company
Most Innovative Companies 2027: Healthcare (pending)
Consumer waitlist
Join 50,000+ families preparing for 2027 launch.
50,247
Families on waitlist · live
Sarah M. from Boston, MA2 min ago
Dr. David L. from Chicago, IL8 min ago
Jennifer K. from Austin, TX15 min ago
FAQ
Frequently asked, transparently answered.
When will APT be available for purchase?+
Q1–Q2 2027, pending FDA 510(k) clearance (expected Q3–Q4 2026) and CE Mark approval.
Is APT FDA approved?+
Not yet. We submitted our 510(k) application in Q2 2026. Approval expected Q3–Q4 2026.
How much will APT cost?+
Estimated $12,000 retail or $199/month financing. Waitlist members receive a $2,000 discount.
Can I join clinical trials?+
Trials are currently full. Join the waitlist to be notified if new sites open.
How can my hospital become a partner?+
Submit a partnership proposal on /partnerships. We're seeking 10–15 launch partners globally.
Will insurance cover APT?+
We're pursuing CPT code designation and CMS coverage. FSA/HSA eligibility confirmed.
Is this HIPAA compliant?+
Our architecture is designed for HIPAA compliance. SOC 2 Type II audit in progress.
How accurate is APT?+
Pilot study (n=50): 89% sensitivity for pancreatic cancer. Multi-center validation underway.
Where is APT manufactured?+
Flex contract manufacturing, ISO 13485-certified facilities in Singapore and Mexico.
Can I invest in Agentic.Plumbing?+
Series A is closed. Series B expected Q1 2027. Accredited investors: investors@agentic.plumbing.
How do I stay updated on FDA approval?+
Join the waitlist or subscribe at /news. We'll announce immediately upon clearance.
What if FDA doesn't approve APT?+
We're confident based on predicate devices and pilot data. If denied, we'll refine and resubmit. Waitlist members can cancel anytime.